ClinicalTrials.gg
CompletedNCT03673670Updated Oct 10, 2019Results posted

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

A Phase 2 interventional study of RPL554 Suspension and Placebo in COPD, sponsored by Verona Pharma plc. Completed at 4 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-10.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
8th of 15
79 · median 79
Started
2018
the only one that year
Phase 2
8 of 15
none open now
Registered
5th of 15
by date
Lead sponsor
9 of 15
Verona Pharma plc

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 2, and was the 5th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol (Respimat) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will receive each of the three treatment combinations in a randomized sequence using a crossover design

Read the detailed description

RPL554 is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) which are known to have a role in modulating the inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or synergistic anti-inflammatory and bronchodilator. The two doses of RPL554 (1.5 mg and 6 mg)have been selected based on the results from prior studies investigating single and multiple ascending doses in healthy subjects, single doses in asthmatics, single/multiple ascending doses in COPD patients, and 3 days of dosing in COPD patients. These doses were demonstrated to be both effective as a bronchodilator and well tolerated.

The purpose of the study is to investigate if RPL554 has an additive bronchodilator effect when administered in combination with a commonly used anticholinergic/β-agonist combination medication, tiotropium/olodaterol (Respimat), in this patient population measured by the peak forced expiratory volume in one second (FEV1), and forced vital capacity (FVC).

03

Conditions studied

  • COPD

Keywords

  • COPD
  • Bronchodilation
  • FEV1
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. Male or female aged 40 and 80 years
  3. For males, not to donate sperm and either be sexually abstinent or use as specified by the protocol. For females, be of non- or use a highly effective form of contraception
  4. 12-lead with heart rate between 45 and 90 beats per minute, ≤450 msec for males, and ≤ 470 msec for females, QRS interval ≤120 msec and no abnormality including morphology
  5. Screening Holter report with a minimum of 18 hours recording that is able to be evaluated for rhythm analysis showing no abnormality which indicates a significant impairment of patient safety or which may significantly impair interpretation
  6. Capable of complying with all study restrictions and procedures including ability to use the study nebulizer and Respimat® correctly.
  7. (BMI) between 18 and 36 kg/m2 and minimum weight of 45 kg.
  8. diagnosis for at least 1 year and clinically stable COPD for 4 week
  9. Post-bronchodilator (two puffs of salbutamol/albuterol followed by two puffs of ipratropium) spirometry at Screening:

    • Post-bronchodilator /forced vital capacity (FVC) ratio of ≤0.70
    • Post-bronchodilator FEV1 ≥30 % and ≤70% of predicted normal
    • Demonstrates ≥150 mL increase from pre-bronchodilator FEV1
  10. A chest X-ray showing no abnormalities, which are both clinically significant and unrelated to COPD.
  1. Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  1. Current and former smokers with smoking history of ≥10 pack years. 14. Capable of withdrawing from long acting bronchodilators for the duration of the study, and short acting bronchodilators for 8 hours prior to dosing.

Exclusion criteria

Exclusion Criteria:

  1. A history of life-threatening including Intensive Care Unit admission and/or requiring intubation.
  2. COPD exacerbation requiring oral or parenteral , or lower respiratory tract infection requiring antibiotics, in the last 3 months
  3. A history of one or more hospitalizations for COPD in the last 12 months
  4. Intolerance or to tiotropium, olodaterol, atropine, ipratropium, or RPL554.
  5. Evidence of cor pulmonale or pulmonary hypertension.
  6. Other respiratory disorders
  7. Previous lung resection or lung reduction surgery.
  8. Use of oral COPD medications, except mucolytics, in the last 3 months
  9. Pulmonary rehabilitation, unless such treatment has been stable in the last 4 weeks
  10. History of, or reason to believe a patient has, drug or alcohol abuse within the past 5 years.
  11. Inability to perform acceptable spirometry or whole body plethysmography
  12. Received an experimental drug within 30 days or five half lives, whichever is longer.
  13. Patients with uncontrolled disease that the Investigator believes are clinically significant. This includes any hepatic disease, or an or aspartate aminotransferase>2 x (ULN).
  14. Documented cardiovascular disease: arrhythmias, angina, recent (\<1 year) or suspected myocardial infarction, congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of hypertension in the last 3 months
  15. Use of non-selective oral β-blockers.
  16. Major surgery (requiring general anesthesia) in the last 6 weeks or will not have fully recovered from surgery, or planned surgery through the end of the study.
  17. A disclosed history or one known to the Investigator, of significant non compliance in previous studies or with prescribed medications.
  18. Required use of oxygen therapy, even on an occasional basis.
  19. Symptomatic prostatic hyperplasia or bladder-neck obstruction or with narrow-angle glaucoma.
  20. History of of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell).
  21. Clinically significant abnormal values for safety laboratory tests (hematology, biochemistry, virology or urinalysis) as determined by the Investigator
  22. Any other reason that the Investigator considers makes the patient unsuitable to participate.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    1.5 mg RPL554 and tiotropium/olodaterol

    1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily

    Drug: RPL554 Suspension · Drug: Tiotropium/olodaterol (Respimat)

  • Experimental
    6 mg RPL554 and tiotropium/olodaterol

    6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily

    Drug: RPL554 Suspension · Drug: Tiotropium/olodaterol (Respimat)

  • Experimental
    Placebo and tiotropium/olodaterol

    Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily

    Drug: Placebo · Drug: Tiotropium/olodaterol (Respimat)

Interventions

  • A PDE3/4 inhibitor

  • DrugPlacebo

    A placebo solution

  • DrugTiotropium/olodaterol (Respimat)

    Drug pages: Tiotropium · Olodaterol

    An anticholinergic/β-agonist combination medication

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Peak FEV1 on Day 3

    Change from baseline FEV1 to peak FEV1 (measured as the greatest value in the 4 hours post-dose after the morning dose) on Day 3

    Time frame: Change from pre-dose at 5, 15 and 30 minutes and 1, 1.5, 2 & 4 hours on Day 3

Secondary outcomes

  1. Change From Baseline to Trough FEV1 on Day 4

    Change from baseline to morning trough FEV1 on Day 4

    Time frame: Change from pre-dose on Day 1 to pre-dose on Day 4

  2. Change From Baseline in AUC0-4h FEV1 on Day 3

    Change from baseline FEV1 to AUC FEV1 over 4 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters. (Note: Endpoint is AUC/interval length (average) so the units are in liters.)

    Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the morning dose)

  3. Change From Baseline in AUC0-12h FEV1 on Day 3

    Change from baseline in AUC over 12 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)

    Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 3 (after the morning dose)

  4. Change From Baseline in Peak FEV1 on Day 1

    Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the morning dose on Day 1

    Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 1 (after the morning dose), with the maximum change reported

  5. Change From Baseline in Peak FEV1 After Evening Dose on Day 3

    Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the evening dose on Day 3

    Time frame: Change from pre-dose to each of the ollowing timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the evening dose), with the maximum change reported

  6. Change From Baseline in AUC0-12h FEV1 on Day 1

    Change from baseline FEV1 to AUC FEV1 over 12 hours post-dose after the morning dose on Day 1. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)

    Time frame: Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 1 (after the morning dose)

  7. Determination of Onset of Action on Day 1

    Time to \>10% increase in FEV1 from pre-first dose, censored at 2 hours

    Time frame: Change from pre-dose to the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2 hours on Day 1 (after the morning dose)

  8. Residual Volume on Day 1

    Change in residual volume during treatment

    Time frame: Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)

  9. Residual Volume on Day 3

    Change in residual volume during treatment

    Time frame: Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)

  10. Functional Residual Capacity on Day 1

    Change in functional residual capacity during treatment

    Time frame: Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)

  11. Functional Residual Capacity on Day 3

    Change in functional residual capacity during treatment

    Time frame: Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)

  12. Specific Airway Conductance on Day 1

    Change in specific airway conductance during treatment

    Time frame: Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)

  13. Specific Airway Conductance on Day 3

    Change in specific airway conductance during treatment

    Time frame: Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)

07

Results

Posted Oct 10, 2019

Participant flow

Treatment Period 1 (3 Days)
Participant flow — Treatment Period 1 (3 Days)
MilestoneLow Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554
Started141413121313
Completed131412121311
Not completed101002
Withdrew: Withdrawal by subject100000
Withdrew: Physician decision001000
Withdrew: Adverse event000001
Withdrew: Alpha 1 antitrypsin deficiency000001
Washout Period 1 (7-14 Days)
Participant flow — Washout Period 1 (7-14 Days)
MilestoneLow Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554
Started131412121311
Completed131412121311
Not completed000000
Treatment Period 2 (3 Days)
Participant flow — Treatment Period 2 (3 Days)
MilestoneLow Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554
Started131412121311
Completed131411121211
Not completed001010
Withdrew: Adverse event001010
Washout Period 2 (7-14 Days)
Participant flow — Washout Period 2 (7-14 Days)
MilestoneLow Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554
Started131411121211
Completed131411121111
Not completed000010
Withdrew: Pre-dose fev1 not 20% baseline000010
Treatment Period 3 (3 Days)
Participant flow — Treatment Period 3 (3 Days)
MilestoneLow Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554
Started131411121111
Completed131411121011
Not completed000010
Withdrew: Adverse event000010

Outcome measures

PrimaryChange From Baseline in Peak FEV1 on Day 3

Change from baseline FEV1 to peak FEV1 (measured as the greatest value in the 4 hours post-dose after the morning dose) on Day 3

Time frame:
Change from pre-dose at 5, 15 and 30 minutes and 1, 1.5, 2 & 4 hours on Day 3
Reported as:
Mean · Liters
Change From Baseline in Peak FEV1 on Day 3
Liters1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Change From Baseline in Peak FEV1 on Day 30.565 ± 0.27830.506 ± 0.25060.519 ± 0.2809
Statistical analysis
  • 1.5 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.168 · Geomean ratio: 1.021 · 95% CI 0.991 to 1.052
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.731 · Geomean ratio: 0.995 · 95% CI 0.966 to 1.025
SecondaryChange From Baseline to Trough FEV1 on Day 4

Change from baseline to morning trough FEV1 on Day 4

Time frame:
Change from pre-dose on Day 1 to pre-dose on Day 4
Reported as:
Mean · Liters
Change From Baseline to Trough FEV1 on Day 4
Liters1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Change From Baseline to Trough FEV1 on Day 40.186 ± 0.24960.178 ± 0.21230.150 ± 0.2218
Statistical analysis
  • 1.5 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.115 · Geomean ratio: 1.024 · 95% CI 0.994 to 1.055
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.111 · Geomean ratio: 1.024 · 95% CI 0.994 to 1.055
SecondaryChange From Baseline in AUC0-4h FEV1 on Day 3

Change from baseline FEV1 to AUC FEV1 over 4 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters. (Note: Endpoint is AUC/interval length (average) so the units are in liters.)

Time frame:
Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the morning dose)
Reported as:
Mean · Liters
Change From Baseline in AUC0-4h FEV1 on Day 3
Liters1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Change From Baseline in AUC0-4h FEV1 on Day 30.429 ± 0.25180.390 ± 0.22460.377 ± 0.2485
Statistical analysis
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.303 · Geomean ratio: 1.014 · 95% CI 0.987 to 1.043
SecondaryChange From Baseline in AUC0-12h FEV1 on Day 3

Change from baseline in AUC over 12 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)

Time frame:
Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 3 (after the morning dose)
Reported as:
Mean · Liters
Change From Baseline in AUC0-12h FEV1 on Day 3
Liters1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Change From Baseline in AUC0-12h FEV1 on Day 30.390 ± 0.24260.347 ± 0.22190.337 ± 0.2447
Statistical analysis
  • 1.5 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.067 · Geomean ratio: 1.027 · 95% CI 0.998 to 1.057
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.395 · Geomean ratio: 1.012 · 95% CI 0.984 to 1.042
SecondaryChange From Baseline in Peak FEV1 on Day 1

Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the morning dose on Day 1

Time frame:
Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 1 (after the morning dose), with the maximum change reported
Reported as:
Mean · Liters
Change From Baseline in Peak FEV1 on Day 1
Liters1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Change From Baseline in Peak FEV1 on Day 10.490 ± 0.22190.467 ± 0.23930.445 ± 0.2306
Statistical analysis
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.404 · Geomean ratio: 1.012 · 95% CI 0.984 to 1.039
SecondaryChange From Baseline in Peak FEV1 After Evening Dose on Day 3

Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the evening dose on Day 3

Time frame:
Change from pre-dose to each of the ollowing timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the evening dose), with the maximum change reported
Reported as:
Mean · Liters
Change From Baseline in Peak FEV1 After Evening Dose on Day 3
Liters1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Change From Baseline in Peak FEV1 After Evening Dose on Day 30.453 ± 0.26250.405 ± 0.25810.324 ± 0.2211
Statistical analysis
  • 1.5 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.001 · Geomean ratio: 1.082 · 95% CI 1.043 to 1.123
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.002 · Geomean ratio: 1.061 · 95% CI 1.023 to 1.101
SecondaryChange From Baseline in AUC0-12h FEV1 on Day 1

Change from baseline FEV1 to AUC FEV1 over 12 hours post-dose after the morning dose on Day 1. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)

Time frame:
Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 1 (after the morning dose)
Reported as:
Mean · Liters
Change From Baseline in AUC0-12h FEV1 on Day 1
Liters1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Change From Baseline in AUC0-12h FEV1 on Day 10.333 ± 0.18150.308 ± 0.18540.303 ± 0.1920
Statistical analysis
  • 1.5 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.096 · Geomean ratio: 1.020 · 95% CI 0.997 to 1.043
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · ANCOVA · p = 0.862 · Geomean ratio: 1.002 · 95% CI 0.979 to 1.025
SecondaryDetermination of Onset of Action on Day 1

Time to \>10% increase in FEV1 from pre-first dose, censored at 2 hours

Time frame:
Change from pre-dose to the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2 hours on Day 1 (after the morning dose)
Reported as:
Median · minutes
Determination of Onset of Action on Day 1
minutes1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Determination of Onset of Action on Day 110.0 (1 to 86)6.0 (4 to 117)11.0 (7 to 120)
Statistical analysis
  • 1.5 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · Wilcoxon (Mann-Whitney) · p = 0.945 · Median difference (final values): 0.0
  • 6 mg RPL554 and Tiotropium/Olodaterol vs Placebo and Tiotropium/Olodaterol · Wilcoxon (Mann-Whitney) · p = 0.501 · Median difference (final values): 0.0
SecondaryResidual Volume on Day 1

Change in residual volume during treatment

Time frame:
Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)
Reported as:
Mean · Liters
Residual Volume on Day 1
Liters1.5 mg RPL554 and Tiotropium/Olodaterol on Day 16 mg RPL554 and Tiotropium/Olodaterol on Day 1Placebo and Tiotropium/Olodaterol on Day 1
Residual Volume on Day 1-0.469 ± 0.5521-0.408 ± 0.4803-0.377 ± 0.4810
SecondaryResidual Volume on Day 3

Change in residual volume during treatment

Time frame:
Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)
Reported as:
Mean · Liters
Residual Volume on Day 3
Liters1.5 mg RPL554 and Tiotropium/Olodaterol on Day 36 mg RPL554 and Tiotropium/Olodaterol on Day 3Placebo and Tiotropium/Olodaterol on Day 3
Pre-dose Day 3-0.323 ± 0.4548-0.313 ± 0.8946-0.184 ± 0.6274
1.25 hours-0.648 ± 0.5173-0.510 ± 0.6304-0.510 ± 0.6257
8.25 hours-0.526 ± 0.5594-0.481 ± 0.4994-0.471 ± 0.6186
12.25 hours-0.353 ± 0.4561-0.236 ± 0.7566-0.094 ± 0.7118
SecondaryFunctional Residual Capacity on Day 1

Change in functional residual capacity during treatment

Time frame:
Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)
Reported as:
Mean · Liters
Functional Residual Capacity on Day 1
Liters1.5 mg RPL554 and Tiotropium/Olodaterol on Day 16 mg RPL554 and Tiotropium/Olodaterol on Day 1Placebo and Tiotropium/Olodaterol on Day 1
Functional Residual Capacity on Day 1-0.344 ± 0.5097-0.294 ± 0.4524-0.277 ± 0.4279
SecondaryFunctional Residual Capacity on Day 3

Change in functional residual capacity during treatment

Time frame:
Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)
Reported as:
Mean · Liters
Functional Residual Capacity on Day 3
Liters1.5 mg RPL554 and Tiotropium/Oldaterol on Day 36 mg RPL554 and Tiotropium/Oldaterol on Day 3Placebo and Tiotropium/Oldaterol on Day 3
1.25 hours-0.490 ± 0.4654-0.408 ± 0.6102-0.382 ± 0.5610
8.25 hours-0.420 ± 0.5003-0.405 ± 0.6111-0.355 ± 0.6004
12.25 hours-0.255 ± 0.4003-0.155 ± 0.7788-0.075 ± 0.5881
Pre-dose on Day 3-0.278 ± 0.4340-0.206 ± 0.5925-0.163 ± 0.5742
SecondarySpecific Airway Conductance on Day 1

Change in specific airway conductance during treatment

Time frame:
Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)
Reported as:
Mean · 1/kPa*sec
Specific Airway Conductance on Day 1
1/kPa*sec1.5 mg RPL554 and Tiotropium/Olodaterol on Day 16 mg RPL554 and Tiotropium/Olodaterol on Day 1Placebo and Tiotropium/Olodaterol on Day 1
Specific Airway Conductance on Day 10.064 ± 0.11480.042 ± 0.04830.043 ± 0.1072
SecondarySpecific Airway Conductance on Day 3

Change in specific airway conductance during treatment

Time frame:
Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)
Reported as:
Mean · 1/kPa*sec
Specific Airway Conductance on Day 3
1/kPa*sec1.5 mg RPL554 and Tiotropium/Olodaterol on Day 36 mg RPL554 and Tiotropium/Olodaterol on Day 3Placebo and Tiotropium/Olodaterol on Day 3
Pre-dose Day 30.021 ± 0.6080.046 ± 0.10600.016 ± 0.0890
1.25 hours0.064 ± 0.08240.050 ± 0.06820.049 ± 0.1193
8.25 hours0.059 ± 0.13120.048 ± 0.07330.037 ± 0.1125
12.25 hours0.029 ± 0.07740.032 ± 0.06290.021 ± 0.1071

Adverse events

Collected over From informed consent until the end of the study, approximately 2 months for each patient. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg RPL554 and Tiotropium/Olodaterol0/75 (0%)0/75 (0%)15/75 (20%)
6 mg RPL554 and Tiotropium/Olodaterol0/74 (0%)1/74 (1.4%)15/74 (20.3%)
Placebo and Tiotropium/Olodaterol0/76 (0%)0/76 (0%)8/76 (10.5%)
Most frequent serious events
Most frequent serious events
Event1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/751/740/76
Most frequent other events
Showing 10 of 20
Most frequent other events
Event1.5 mg RPL554 and Tiotropium/Olodaterol6 mg RPL554 and Tiotropium/OlodaterolPlacebo and Tiotropium/Olodaterol
HeadacheNervous system disorders5/755/741/76
Ventricular extrasystolesCardiac disorders2/753/740/76
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/752/741/76
HypertensionVascular disorders0/752/741/76
BronchospasmRespiratory, thoracic and mediastinal disorders0/751/741/76
ConstipationGastrointestinal disorders0/751/740/76
Blood glucose increasedInvestigations0/751/740/76
Electrocardiogram QT prolongedInvestigations1/751/740/76
Upper limb fractureInjury, poisoning and procedural complications0/751/740/76
Muscle spasmsMusculoskeletal and connective tissue disorders1/751/741/76

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554Total
Median65.5 (43 to 75)64.5 (53 to 74)63.0 (45 to 74)63.0 (43 to 77)67.0 (49 to 76)61.0 (48 to 73)64.0 (43 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554Total
Female99878849
Male55555530
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose RPL554 Then High Dose RPL554 Then PlaceboLow Dose RPL554 Then Placebo Then High Dose RPL554High Dose RPL554 Then Low Dose RPL554 Then PlaceboHigh Dose RPL554 Then Placebo Then Low Dose RPL554Placebo Then Low Dose RPL554 Then High Dose RPL554Placebo Then High Dose RPL554 Then Low Dose RPL554Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000011
Black or African American1112016
White13131210131172
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

4 sites
  • Clinical Site Partners, LLC
    Winter Park, Florida 32789, United States
  • Allied Biomedical Research Holdings, d/b/a Vitalink Research
    Greenville, South Carolina 29615, United States
  • Respiratory Clinical Trials LTD,
    London, W1G8HU, United Kingdom
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Nov 2018, 3 months.

Results were first posted in Oct 2019, 10 months after primary completion.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 3 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2018
First posted
Sep 17, 2018
StartActual
Jul 16, 2018
Primary completionActual
Nov 13, 2018
CompletionActual
Nov 13, 2018
Results first posted
Oct 10, 2019
Last update
Oct 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03673670
Lead sponsor
Verona Pharma plc
Responsible party
Sponsor
First posted
Sep 17, 2018
Start date
Jul 16, 2018
Primary completion
Nov 13, 2018
Completion
Nov 13, 2018
Results posted
Oct 10, 2019
Last update
Oct 10, 2019

Study contacts

Dave Singh
principal investigator · Medicines Evaluation Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion